CVS reportedly cites pricing concerns in excluding coverage for Gilead’s new HIV drug

Pricing issues have taken precedence as CVS Health’s (NYSE:CVS) pharmacy benefit manager, CVS Caremark, continues to hold off ...
Commercial Appeal

Federal HIV funding rerouted to nonprofits, bypasses Tennessee health department entirely

Nearly three months after the Tennessee Health Department said it would no longer accept and distribute federal funding for HIV prevention-related services, the U.S. Centers for Disease Control and ...
European Medical Journal

IDWeek 2025: HIV Prevention Breakthrough Could Cost $25 Annually

A new analysis finds that generic lenacapavir, a twice-yearly HIV preventive treatment, could be mass produced for just $25 ...
Benzinga.com

CVS Health Declines To Add Gilead's Steeply Priced New HIV Prevention Drug To Its Plans

CVS Health Inc. (NYSE:CVS) said it will not add Gilead Sciences Inc.’s (NASDAQ:GILD) new HIV prevention drug Yeztugo to its commercial plans. In June, the U.S. Food and Drug Administration (FDA) ...
Commercial Appeal

HIV funding stopped for Tennessee nonprofits: Here's what we know

Editor's note: This story has been updated to clarify which federal programs will not be impacted. Organizations across Tennessee were informed Wednesday that federal funding they have for years ...
Medscape

HBV Reactivation Risk Low After Tenofovir Cessation in HIV

HBcAb-positive, HBsAg-negative people with HIV can safely switch from tenofovir-containing ART without clinically significant HBV reactivation.
Business Insider

Biostax Announces FINRA Approval for Name and Ticker Symbol Change, Signals Entry into Global Substance Abuse Commercial Markets and Pioneering HIV Treatment

ORLANDO, Fla., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Biostax Corp (OTC Pink: BTAX), a leading public company specializing in healthcare solutions, today announced a milestone in its transformative ...